A study from the Barcelona Checkpoint gay men’s HIV clinic, presented at the recent 15th European AIDS Conference, has found a strong and consistent relationship between the annual HIV infection rate (incidence) of different categories of clinic users and the particular combination of risk factors they self-report. The primary intention behind this study was to estimate what proportion of clinic users might benefit from HIV pre-exposure prophylaxis (PrEP). In doing the exercise, however, the clinic also managed to establish interesting new estimates for the relative contribution to HIV risk of condomless sex, sexually transmitted infections, high sex partner numbers, and sexual role.
An Australian research team has found that disulfiram, a long-established and safe drug used primarily as a treatment for alcohol dependency (well-known under its brand name Antabuse) can "wake up" quiescent HIV-infected reservoir cells and thus be used as the first stage of a hypothetical cure for HIV. The research was reported in the November 16 online edition of The Lancet HIV.
Re-treating with an interferon-free regimen that previously failed to cure hepatitis C can result in success if treatment is intensified with the addition of sofosbuvir (Sovaldi), a pair of studies presented at the AASLD Liver Meeting this week in San Francisco have shown.
An all-oral combination of daclatasvir, sofosbuvir, and ribavirin taken for 12 or 16 weeks led to high sustained virological response rates for people with hard-to-treat hepatitis C virus (HCV) genotype 3 and advanced liver fibrosis or cirrhosis, according to findings from the ALLY-3+ study presented at the 2015 AASLD Liver Meeting this week in San Francisco.